Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Steven A Everett
AddedMar 31, 2024
UpdatedMay 31, 2026
Steven A Everett

Steven A Everett

Founder & CEO, MaveriX Oncology

Crunchbase

Steven A Everett's Career

MaveriX Oncology
MaveriX Oncology

Palo Alto, CA, US

Founder & CEO· C-Suite · Management
Cyterix Pharmaceuticals
Cyterix Pharmaceuticals

San Francisco, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Steven A Everett's Career

MaveriX Oncology
MaveriX Oncology
Series A$6.5M22014Palo Alto, CA, US
Founder & CEO· C-Suite · Management

Similar to MaveriX Oncology

CancervaxCancervaxSanta Barbara, CA, USCancer Treatmentest. 2021CancervaxSanta Barbara, CA, US · est. 2021

CancerVAX Biotech: Santa Barbara-based medical firm innovating universal cancer treatments.

Seed · $500k13
Imvaq TherapeuticsImvaq TherapeuticsNew York City, NY, USCancer Treatmentest. 2018Imvaq TherapeuticsNew York City, NY, US · est. 2018

Imvaq: A biotech firm innovating immuno-oncologics for global cancer treatment.

Series B · $20M8
Vivacitas OncologyVivacitas OncologyWalnut Creek, CA, USCancer Therapiesest. 2015Vivacitas OncologyWalnut Creek, CA, US · est. 2015

Vivacitas Oncology: Innovating biopharmaceutical solutions for resistant cancers since 2015.

Seed · $100k11
Minerva BiotechnologiesMinerva BiotechnologiesWaltham, MA, USCancer Therapiesest. 1999Minerva BiotechnologiesWaltham, MA, US · est. 1999

US-based Minerva Biotechnologies develops innovative cancer immunotherapies and drugs targeting solid tumors.

Series A · $70M24
Cyterix Pharmaceuticals
Cyterix Pharmaceuticals
Acquired$16.5M02010San Francisco, CA, US
Board Member· Board

Leadership at Cyterix Pharmaceuticals

Tim KutzkeyTim KutzkeyBoard Member
Dr Lutz B GiebelDr Lutz B GiebelBoard Member

Similar to Cyterix Pharmaceuticals

CytomX TherapeuticsCytomX TherapeuticsSouth San Francisco, CA, USCancer Treatmentsest. 2010CytomX TherapeuticsSouth San Francisco, CA, US · est. 2010

CytomX Therapeutics: A US-based oncology-focused biopharmaceutical firm specializing in probody cancer treatments.

Public · $345.4M174
OncolixOncolixHouston, TX, USCancer Treatmentest. 2007OncolixHouston, TX, US · est. 2007

Oncolix: A clinical-stage biotech firm innovating therapeutic proteins for cancer treatment.

Series A · $8.5M30
Altiris TherapeuticsAltiris TherapeuticsAtlanta, GA, USCancer Drugs, HIV Drugsest. 2005Altiris TherapeuticsAtlanta, GA, US · est. 2005

Innovative cancer and HIV drug developer. Founded in 2005.

Public · $46.3M750
Novita PharmaceuticalsNovita PharmaceuticalsNew York City, NY, USCancer Drugsest. 2010Novita PharmaceuticalsNew York City, NY, US · est. 2010

Novita Pharmaceuticals: Developing and providing cancer-treatment drugs since 2010, based in New York.

Series A · $8.5M7

Steven A Everett's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Steven A Everett

David MandelkernDavid MandelkernCo-Founder · SumTotal SystemsSteven YeciesSteven YeciesFounder · ScientBrian MarcotteBrian MarcotteBoard Member · Carrot FertilityKent MarquardtKent MarquardtBoard Member · OpalaLaura E. BenjaminLaura E. BenjaminFounder · OncXerna TherapeuticsSteven JamesSteven JamesBoard Member · Armetheon